Arsenic trioxide mutational spectrum analysis in the mouse lymphoma assay

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 646, Issue 1-2, 2008, Pages 1-7

  Soriano, Carolina ^a,b   Creus, Amadeu ^a   Marcos, Ricard ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Arsenic trioxide (ATO, As2O3); Mouse lymphoma assay; Mutational spectrum; Tk locus

Indexed keywords

ARSENIC TRIOXIDE; THYMIDINE KINASE;

ANIMAL CELL; ARTICLE; CHROMOSOME 11; CHROMOSOME DELETION; CONTROLLED STUDY; GENE MUTATION; GENOTOXICITY; HETEROZYGOSITY LOSS; LYMPHOMA CELL; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ARSENICALS; BIOLOGICAL ASSAY; CELL LINE, TUMOR; LEUKEMIA L5178; LEUKEMIA, PROMYELOCYTIC, ACUTE; MICE; MUTAGENICITY TESTS; OXIDES; SPECTRUM ANALYSIS; THYMIDINE KINASE;

EID: 54149117788     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2008.08.014     Document Type: Article

References (61)

1. Antman K.H. Introduction: the history of arsenic trioxide in cancer therapy. Oncologist 6 Suppl. 2 (2001) 1-2
2. 3) in the treatment of patients with acute promyelocytic leukemia. The M.D. Anderson experience. Cancer 97 (2003) 2218-2224
3. Soignet S.L., Maslak P., Wang Z.G., Jhanwar S., Calleja E., Dardashti L.J., Corso D., DeBlasio A., Gabrilove J., Scheinberg D.A., Pandolfi P.P., and Warrell Jr. R.P. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med. 339 (1998) 1341-1348
4. Lengfelder E., Saussele S., Weisser A., Buchner T., and Hehlmann R. Treatment concepts of acute promyelocytic leukemia. Crit. Rev. Oncol. Hematol. 56 (2005) 261-274
5. Monzen H., Griffin R.J., Williams B.W., Amano M., Ando S., and Hasegawa T. Study of arsenic trioxide-induced vascular shutdown and enhancement with radiation in solid tumor. Radiat. Med. 22 (2004) 205-211
6. Shen Z.Y., Zhang Y., Chen J.Y., Chen M.H., Shen J., Luo W.H., and Zeng Y. Intratumoral injection of arsenic to enhance antitumor efficacy in human esophageal carcinoma cell xenografts. Oncol. Rep. 11 (2004) 155-159
7. Pu Y.S., Hour T.C., Chen J., Huang C.Y., Guan J.Y., and Lu S.H. Arsenic trioxide as a novel anticancer agent against human transitional carcinoma-characterizing its apoptotic pathway. Anticancer Drugs 13 (2002) 293-300
8. Naito K., Kobayashi M., Sahara N., Shigeno K., Nakamura S., Shinjo K., Tobita T., Takeshita A., Ohno R., and Ohnishi K. Two cases of acute promyelocytic leukemia complicated by torsade de pointes during arsenic trioxide therapy. Int. J. Hematol. 83 (2006) 318-323
9. Evens A.M., Tallman M.S., and Gartenhaus R.B. The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. Leuk. Res. 28 (2004) 891-900
10. Li Y., Sun X., Wang L., Zhou Z., and Kang Y.J. Myocardial toxicity of arsenic trioxide in a mouse model. Cardiovasc. Toxicol. 2 (2002) 63-73
11. IARC, Some Drinking-water Disinfectants and Contaminants Including Arsenic. Monographs on the Evaluation of the Carcinogenic Risk to Humans, vol. 84, IARC, Scientific Publication, Lyon, 2004.
12. IARC, Arsenic and Arsenic Compounds. Monographs on the Evaluation of the Carcinogenic Risk to Humans, Suppl. 7, IARC, Scientific Publication, Lyon, 1987.
13. Rossman T.G. Mechanism of arsenic carcinogenesis: an integrated approach. Mutat. Res. 533 (2003) 37-65
14. Basu A., Mahata J., Gupta S., and Giri A.K. Genetic toxicology of a paradoxical human carcinogen, arsenic: a review. Mutat. Res. 488 (2001) 171-194
15. Abernathy C.O., Liu Y.P., Longfellow D., Aposhian H.V., Beck B., Fowler B., Goyer R., Menzer R., Rossman T., Thompson C., and Waalkes M. Arsenic: health effects, mechanisms of actions, and research issues. Environ. Health Perspect. 107 (1999) 593-597
16. Ayala-Fierro F., Barber D.S., Rael L.T., and Carter D.E. In vitro tissue specificity for arsine and arsenite toxicity in the rat. Toxicol. Sci. 52 (1999) 122-129
17. Lee T.C., Tzeng S.F., Chang W.J., Lin Y.C., and Jan K.Y. Post-treatments with sodium arsenite during G2 enhance the frequency of chromosomal aberrations induced by S-dependent clastogens. Mutat. Res. 163 (1986) 263-269
18. Lee T.C., Tanaka N., Lamb P.W., Gilmer T.M., and Barrett J.C. Induction of gene amplification by arsenic. Science 241 (1988) 79-81
19. Jha A.N., Noditi M., Nilsson R., and Natarajan A.T. Genotoxic effects of sodium arsenite on human cells. Mutat. Res. 284 (1992) 215-221
20. Wiencke J.K., and Yager J.W. Specificity of arsenite in potentiating cytogenetic damage induced by the DNA crosslinking agent diepoxybutane. Environ. Mol. Mutagen. 19 (1992) 195-200
21. Wang T.S., Shu Y.F., Liu Y.C., Jan K.Y., and Huang H. Glutathione peroxidase and catalase modulate the genotoxicity of arsenite. Toxicology 121 (1997) 229-237
22. Gebel T.W. Unanswered questions in arsenic toxicology. J. Environ. Pathol. Toxicol. Oncol. 20 (2001) 299-309
23. Noda Y., Suzuki T., Kohara A., Hasegawa A., Yotsuyanagi T., Hayashi M., Sofuni T., Yamanaka K., and Okada S. In vivo genotoxicity evaluation of dimethylarsinic acid in MutaMouse. Mutat. Res. 513 (2002) 205-212
24. Hei T.K., Liu S.X., and Waldren C. Mutagenicity of arsenic in mammalian cells: role of reactive oxygen species. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 8103-8107
25. Moore M.M., Harrington-Brock K., and Doerr C.L. Relative genotoxic potency of arsenic and its methylated metabolites. Mutat. Res. 386 (1997) 279-290
26. Meng Z., and Hsie A.W. Polymerase chain reaction-based deletion analysis of spontaneous and arsenite-enhanced gpt mutants in CHO-AS52 cells. Mutat. Res. 356 (1996) 255-259
27. Li J.H., and Rossman T.G. Comutagenesis of sodium arsenite with ultraviolet radiation in Chinese hamster V79 cells. Biol. Met. 4 (1991) 197-200
28. Soriano C., Creus A., and Marcos R. Gene-mutation induction by arsenic compounds in the mouse lymphoma assay. Mutat. Res. 634 (2007) 40-50
29. Honma M., Hayashi M., Shimada H., Tanaka N., Wakuri S., Awogi T., Yamamoto K.I., Kodani N., Nishi Y., Nakadate M., and Sofuni T. Evaluation of the mouse lymphoma Tk assay (microwell method) as an alternative to the in vitro chromosomal aberration test. Mutagenesis 14 (1999) 5-22
30. Clive D., Bolcsfoldi G., Clements J., Cole J., Homna M., Majeska J., Moore M., Müller L., Myhr B., Oberly T., Oudelhkim M.-C., Rudd C., Shimada H., Sofuni T., Thybaud V., and Wilcox P. Consensus agreement regarding protocol issues discussed during the mouse lymphoma workshop: Portland, Oregon, May 7, 1994. Environ. Mol. Mutagen. 25 (1995) 165-168
31. -/- mouse lymphoma mutants by loss of heterozygosity (LOH) and by whole chromosome 11 painting: detection of recombination. Mutagenesis 13 (1998) 461-474
32. Liechty M.C., Crosby Jr. H., Murthy A., Davis L.M., Caspary W.J., and Hozier J.C. Identification of a heteromorphic microsatellite within the thymidine kinase gene in L5178Y mouse lymphoma cells. Mutat. Res. 371 (1996) 265-271
33. Chen T., Harrington-Brock K., and Moore M.M. Mutant frequency and mutational spectra in the Tk and Hprt genes of N-ethyl-N-nitrosourea-treated mouse lymphoma cellsdagger. Environ. Mol. Mutagen. 39 (2002) 296-305
34. Moore M.M., Honma M., Clements J., Bolcsfoldi G., Burlinson B., Cifone M., Clarke J., Delongchamp R., Durward R., Fellows M., Gollapudi B., Hou S., Jenkinson P., Lloyd M., Majeska J., Myhr B., O'Donovan M., Omori T., Riach C., San R., Stankowski Jr. L.F., Thakur A.K., Van Goethem F., Wakuri S., and Yoshimura I. Mouse lymphoma thymidine kinase gene mutation assay: follow-up meeting of the International Workshop on Genotoxicity Testing, Aberdeen, Scotland, 2003. Assay acceptance criteria, positive controls, and data evaluation. Environ. Mol. Mutagen. 47 (2006) 1-5
35. Patlolla A.K., and Tchounwou P.B. Cytogenetic evaluation of arsenic trioxide toxicity in Sprague-Dawley rats. Mutat. Res. 587 (2005) 126-133
36. Yedjou C.G., and Tchounwou P.B. In-vitro cytotoxic and genotoxic effects of arsenic trioxide on human leukemia (HL-60) cells using the MTT and alkaline single cell gel electrophoresis (Comet) assays. Mol. Cell. Biochem. 301 (2007) 123-130
37. Abdullaev F.I., Rivera-Luna R., García-Carrancá A., Ayala-Fierro F., and Espinosa-Aguirre J.J. Cytotoxic effect of three arsenic compounds in HeLa human tumor and bacterial cells. Mutat. Res. 493 (2001) 31-38
38. Rossman T.G., Stone D., Molina M., and Troll W. Absence of arsenite mutagenicity in E. coli and Chinese hamster cells. Environ. Mutagen. 2 (1980) 371-379
39. IARC, Some Metals and Metallic Compounds. Monographs on the Evaluation of the Carcinogenic Risk to Humans, vol. 23, IARC, Scientific Publication, Lyon, 1980.
40. Kligerman A.D., Doerr C.L., Tennant A.H., Harrington-Brock K., Allen J.W., Winkfield E., Poorman-Allen P., Kundu B., Funasaka K., Roop B.C., Mass M.J., and DeMarini D.M. Methylated trivalent arsenicals as candidate ultimate genotoxic forms of arsenic: induction of chromosomal mutations but not gene mutations. Environ. Mol. Mutagen. 42 (2003) 192-205
41. Daviet S., Couvé-Privat S., Gros L., Shinozuka K., Ide H., Saparbaev M., and Ishchenko A.A. Major oxidative products of cytosine are substrates for the nucleotide incision repair pathway. DNA Repair 6 (2007) 8-18
42. Lee D.H., O'Connor T.R., and Pfeifer G.P. Oxidative DNA damage induced by copper and hydrogen peroxide promotes CG → TT tandem mutations at methylated CpG dinucleotides in nucleotide excision repair-deficient cells. Nucleic Acids Res. 30 (2002) 3566-3573
43. Hei T.K., and Filipic M. Role of oxidative damage in the genotoxicity of arsenic. Free Radic. Biol. Med. 37 (2004) 574-581
44. Duker A.A., Carranza E.J., and Hale M. Arsenic geochemistry and health. Environ. Int. 31 (2005) 631-641
45. Salnikow K., and Zhitkovich A. Genetic and epigenetic mechanisms in metal carcinogenesis and cocarcinogenesis: nickel, arsenic, and chromium. Chem. Res. Toxicol. 21 (2008) 28-44
46. Kitchin K.T., and Ahmad S. Oxidative stress as a possible mode of action for arsenic carcinogenesis. Toxicol. Lett. 137 (2003) 3-13
47. Kitchin K.T. Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. Toxicol. Appl. Pharmacol. 172 (2001) 249-261
48. Ramírez T., Stopper H., Fischer T., Hock R., and Herrera L.A. S-adenosyl-l-methionine counteracts mitotic disturbances and cytostatic effects induced by sodium arsenite in HeLa cells. Mutat. Res. 637 (2007) 152-160
49. Yih L.H., and Lee T.C. Effects of exposure protocols on induction of kinetochore-plus and -minus micronuclei by arsenite in diploid human fibroblasts. Mutat. Res. 440 (1999) 75-82
50. Eguchi N., Kuroda K., and Endo G. Metabolites of arsenic induced tetraploids and mitotic arrest in cultured cells. Arch. Environ. Contam. Toxicol. 32 (1997) 141-145
51. Ramírez P., Eastmond D.A., Laclette J.P., and Ostrosky-Wegman P. Disruption of microtubule assembly and spindle formation as a mechanism for the induction of aneuploid cells by sodium arsenite and vanadium pentoxide. Mutat. Res. 386 (1997) 291-298
52. Vega L., Gonsebatt M.E., and Ostrosky-Wegman P. Aneugenic effect of sodium arsenite on human lymphocytes in vitro: an individual susceptibility effect detected. Mutat. Res. 334 (1995) 365-373
53. Moore L.E., Warner M.L., Smith A.H., Kalman D., and Smith M.T. Use of the fluorescent micronucleus assay to detect the genotoxic effects of radiation and arsenic exposure in exfoliated human epithelial cells. Environ. Mol. Mutagen. 27 (1996) 176-184
54. Kligerman A.D., Doerr C.L., and Tennant A.H. Oxidation and methylation status determine the effects of arsenic on the mitotic apparatus. Mol. Cell. Biochem. 279 (2005) 113-121
55. Soignet S.L. Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia. Oncologist 6 Suppl. 2 (2001) 11-16
56. Liu B., Pan S., Dong X., Qiao H., Jiang H., Krissansen G.W., and Sun X. Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice. Cancer Sci. 97 (2006) 675-681
57. Verma R.J., Vasu A., and Saiyed A.A. Arsenic toxicity in mice and its possible amelioration. J. Environ. Sci. (China) 16 (2004) 447-453
58. Wang S.S., Zhang T., Wang X.L., Hong L., and Qi Q.H. Effect of arsenic trioxide on rat hepatocellular carcinoma and its renal cytotoxity. World J. Gastroenterol. 9 (2003) 930-935
59. Hsueh Y.M., Ko Y.F., Huang Y.K., Chen H.W., Chiou H.Y., Huang Y.L., Yang M.H., and Chen C.J. Determinants of inorganic arsenic methylation capability among residents of the Lanyang Basin: arsenic and selenium exposure and alcohol consumption. Toxicol. Lett. 137 (2003) 49-63
60. Cullen W.R., and Reimer K.J. Arsenic speciation in the environment. Chem. Rev. 89 (1989) 713-764
61. Kligerman A.D., and Tennant A.H. Insights into the carcinogenic mode of action of arsenic. Toxicol. Appl. Pharmacol. 222 (2007) 281-288